Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO News

30/11/2015 11:12

Manfield Chemical (01561) retail IPO 66.5x over-subscribed

[ET Net News Agency, 30 November 2015] Manfield Chemical (01561) said its retail
offering was over-subscribed by about 66.5 times and the placing was moderately
over-subscribed by about 3.3 times.
The offer price is fixed at HK$1 per share, with estimated net proceeds of about
HK$121.5 million.
Dealings in shares of Manfield Chemical are expected to commence tomorrow morning, with
a board lot size of 4,000 shares each.
Manfield Chemical commenced the manufacture of industrial coatings in 1986 under
Manfield Coatings. Since then, it has expanded operations and it currently undertakes
coating production and sales primarily from three production facilities located in
Shenzhen, Guangzhou and Changzhou and its headquarters located in Hong Kong. (HL)

Back to IPO News

A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.